It is the stuff of parental nightmares. Between July and October 70 kids in Gambia died of kidney failure. In December 18 perished in Uzbekistan from renal issues and acute respiratory illness. In each instances Indian-made cough syrups could have been at fault, in line with allegations by a Gambian parliamentary committee and the Uzbek authorities.
Listen to this story. Enjoy extra audio and podcasts on iOS or Android.
Your browser doesn’t help the <audio> aspect.
Save time by listening to our audio articles as you multitask
OK
The producer within the Uzbek case, Marion Biotech, has been suspended from Pharmexcil, an Indian government-linked commerce group that performs a task in pharmaceutical exports; the agency’s web site seems to be down. An government for Maiden Pharma, which produced the drugs utilized in Gambia, instructed an Indian newspaper that the corporate was shocked and saddened by the deaths. The agency posted a report on its Facebook web page claiming {that a} authorities drug-testing lab in India had discovered its syrup to be problem-free; unpersuaded Gambian parliamentarians really useful that Maiden ought to be prosecuted. Neither agency responded to The Economist’s requests for remark.
Both firms are small and privately held. A causal hyperlink between their merchandise and the deaths has not been proved. Sample exams in India have up to now cleared Maiden of blame; an investigation of Marion has simply begun. Yet the incidents have touched a uncooked nerve in India’s huge pharmaceutical business, the place round 10,000 factories operated by 3,000 corporations churn out almost $50bn-worth of medication a yr, accounting for 20% of the world’s and 40% of America’s generics provide by worth.
The world’s pharmacy, as India’s drugmakers prefer to name themselves, isn’t any stranger to scandal. In 2022 America’s Food and Drug Administration issued “import alerts” to 4 massive Indian firms. Such notifications, which often observe inspections of overseas factories, may result in exports to America…
2023-01-05 09:20:04 A scandal rocks India’s pharmaceutical business
Link from www.economist.com